Three vaccine developers received $60 million in emergency funding to develop treatments for the Bundibugyo strain of Ebola spreading across the Democratic Republic of the Congo and Uganda. The outbreak poses particular challenges due to security issues and conflict in affected regions, but coordinated vaccine development efforts are underway to contain transmission.
Guardian Global Development · Thursday, 4 June 2026
#vaccine development#emergency funding#Ebola#public health#disease outbreak
With the Bundibugyo strain of the disease spreading across the DRC and Uganda, scientists and researchers are trying to find rapid solutionsThere is no vaccine or treatment available for the Bundibugyo strain of Ebola that is spreading in the Democratic Republic of the Congo (DRC) and Uganda, but this week three vaccine developers were awarded $60m (£45m) in emergency funding as the race to halt the outbreak ramps up.Security issues in the affected region of the DRC, where conflict has displaced tens of thousands, have made it challenging to set up trials to test drugs. Militias operate in the area and some Ebola treatment centres have been attacked. Continue reading...